Roche CE mark Contivue advances Susvimo for nAMD in Europe, potentially benefiting 1.7 million people.
Author: PharmaSignal News Desk
Gilead AI manufacturing hub breaks ground in US, creating over 3,000 jobs and boosting biopharma innovation.
OMass Genentech collaboration targets inflammatory bowel disease with a $400 million deal, leveraging OdyssION platform.
Biohaven Vyglxia FDA approval leads to launch preparations, with a patient hub and sales force ready.
FDA approves Leqembi Iqlik as a weekly subcutaneous injection for Alzheimer’s, enhancing patient convenience and safety.
Avadel licenses sleep drug for $20M upfront, expanding its portfolio with XWPharma’s valiloxybate.
Gilead HIV drug prices increase significantly, while Novartis enters a $5.2 billion licensing deal with Argo Biopharmaceutical.
Enveda Biosciences funding reaches $300M to develop drugs for immune and obesity conditions, including atopic dermatitis and asthma.
FDA ultra-rare disease drugs review pathway targets conditions affecting fewer than 1,000 people in the U.S.
Pharma industry executives expect the recent GST rate cut to serve as a booster for contract manufacturers, while on the issue of input tax credit (ITC) — arising from the 18 per tax on APIs — leaders suggest that faster processing of refunds could help to recover the invested capital and ease tax liability.